GENELUX CORPORATION Amortization of Debt Discount (Premium)
GENELUX CORPORATION (GNLX) reported Amortization of Debt Discount (Premium) of $649.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2025-03-28
- GENELUX CORPORATION amortization of debt discount (premium) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION amortization of debt discount (premium) for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION amortization of debt discount (premium) for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION amortization of debt discount (premium) for the quarter ending 2023-03-31 was $649.00K, a 1224.49% increase year-over-year.
- GENELUX CORPORATION amortization of debt discount (premium) for fiscal 2023 was $649.00K, a 151.55% increase from fiscal 2022.
- GENELUX CORPORATION amortization of debt discount (premium) for fiscal 2022 was $258.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 derived: sum of 3 quarters · filed 2025-03-28 | $649.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $649.00K 10-Q · filed 2024-11-14 | $759.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $649.00K 10-Q · filed 2024-08-14 | $759.00K derived: sum of 3 quarters · filed 2024-08-14 | $808.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $649.00K 10-Q · filed 2024-05-09 | $759.00K derived: sum of 2 quarters · filed 2024-05-09 | $808.00K derived: sum of 3 quarters · filed 2024-05-09 | $858.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $159.00K derived: sum of 2 quarters · filed 2024-03-29 | $209.00K derived: sum of 3 quarters · filed 2024-03-29 | $258.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $49.00K 10-Q · filed 2023-11-14 | $99.00K derived: sum of 2 quarters · filed 2023-11-14 | $148.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $50.00K 10-Q · filed 2023-08-14 | $99.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |